Stock 688179 SHANGHAI ALADDIN BIOCHEMICAL TECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Aladdin Biochemical Technology Co.,Ltd.

Equities

688179

CNE100005XD0

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
17.01 CNY -0.82% Intraday chart for Shanghai Aladdin Biochemical Technology Co.,Ltd. +6.11% -11.22%
Apr. 29 Shanghai Aladdin Biochemical Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 19 Shanghai Aladdin Biochemical Technology Co.,Ltd. agreed to acquire 51% stake in Shanghai Yuanye Biotechnology Co., Ltd. for CNY 180 million from Cui Yuanyuan and Tan Xiaoyong. CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI ALADDIN BIOCHEMICAL TECHNOLOGY CO.,LTD. Stock Shanghai Aladdin Biochemical Technology Co.,Ltd.
-11.22% 466M -
MODERNA, INC. Stock Moderna, Inc.
+22.56% 46.71B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.51% 41.52B
B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
A
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.55B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.13% 25.78B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.44% 19.26B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 11.98B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.14% 12.14B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 12.08B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. 688179 Stock
  4. Ratings Shanghai Aladdin Biochemical Technology Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW